It seems that psychedelic treatments may soon be part of the therapy for treating mental health disorders. Investors are increasingly opening their minds and wallets to the possibilities of psychedelic-assisted therapies.
Among the classical psychedelic substances are MDMA, known as “ecstasy” or “molly,” LSD, and psilocybin from magic mushrooms.
Used under medical supervision, research shows for now that psilocybin would influence treating mental disorders that are difficult to treat by “reshaping” how parts of the brain communicate with each other.
Psilocybin acts twice as fast and has significantly better effects on depression compared to standard treatments, according to the results of recent research. According to expert data, this compound has caused “significant improvements” in the ability of patients to express emotions and feel pleasure. There have also been visible decreases in the direction of suicidal intentions and anxiety, as well as an increase in well-being.
Among the challenges facing future testing is the expansion of the test groups, the diversification of the tested categories, and the determination of the correct doses of psilocybin so that the treatment does not cause addiction – for which the antidepressants have gained sad fame. In addition, given that psilocybin is illegal, studies are carried out at a slower pace and only on psilocybin spores, these being the only compounds of magic mushrooms that can be used in laboratory research. Researchers can find psilocybin spores for sale legally for research purposes only at https://shamanmushroomspores.com. Educated lab technicians and professional staff at Shaman work under strict industry protocols to ensure microscopic research standards are met.